Options Exercise: Janux Executive Sells 16,665 Shares for $501,000

Meyer Andrew Hollman, Chief Business Officer at Janux Therapeutics (JANX 1.70%), exercised 16,665 options and immediately sold the resulting shares for a transaction value of approximately $501,000 on October 28, 2025, according to a recent SEC Form 4 filing.

The Motley Fool • Dec 4, 2025

Janux dives as gaps in prostate cancer study data worry investors

Shares of Janux Therapeutics slumped nearly 50% on Tuesday as investors reacted to limited disclosure in the company's early-stage study update for its prostate cancer treatment.

Reuters • Dec 2, 2025

Janux Therapeutics Craters 50% On Prostate Cancer Update; Is It An 'Overreaction'?

Janux Therapeutics stock crashed Tuesday on what one analyst called an "overreaction" to the company's prostate cancer treatment update.

Investors Business Daily • Dec 2, 2025

Janux Therapeutics Stock Hits 52-Week Low After Trial Update

Janux Therapeutics Inc. (NASDAQ: JANX) stock hit a 52-week low on Tuesday after the company released updated interim data for its JANX007 Phase 1 program for metastatic castration-resistant prostate cancer (mCRPC).

Benzinga • Dec 2, 2025

Janux Therapeutics Stock Craters After ‘Positive' Cancer Drug Trial Data. Why It's Down 41%.

Janux posts what it called ‘positive trial data' for its novel treatment in patients with late-stage prostate cancer.

Barrons • Dec 2, 2025

Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday.

Benzinga • Dec 2, 2025

Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript

Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript

Seeking Alpha • Dec 2, 2025

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC.

Business Wire • Dec 1, 2025

Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced it will host a virtual event on Monday, December 1, 2025, at 4:30 PM ET. David Campbell, Ph.D., President & Chief Execu.

Business Wire • Nov 24, 2025

Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. "With enrollment ongoing i.

Business Wire • Nov 6, 2025